v3.26.3
Interim Condensed Consolidated Statements of Cash Flows (Parenthetical) - Chemomab Therapeutics Ltd [Member] - USD ($)
$ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Defined Benefit Plan Disclosure [Line Items]          
Change in employees and related expenses $ 147 $ (488) $ (278) [1] $ 111 [1] $ (737) [1]
Change in accrued expenses 156 (915) (1,202) [2] (1,887) [2] 45 [2]
Share-based compensation $ 221 $ 245 623 [3] 617 [3] 1,491 [3]
Related Party [Member]          
Defined Benefit Plan Disclosure [Line Items]          
Change in employees and related expenses     73 41  
Change in accrued expenses     1 1  
Share-based compensation     $ 389 $ 427 $ 1,304
[1] Includes changes in balances due to related parties of ($73) thousand and $41 thousand for the years ended December 31, 2025 and 2024, respectively. See Note 12.
[2] Includes changes in balances due to related parties of ($1) thousand and $1 thousand for the years ended December 31, 2025 and 2024, respectively. See Note 12.
[3] Includes expenses related to related parties of $389 thousand, $427 thousand and $1,304 thousand for the years ended December 31, 2025, 2024 and 2023, respectively. See Note 12.